Apeloa Pharmaceutical Co Ltd
SZSE:000739
EV/EBIT
Enterprise Value to EBIT
Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.
Market Cap | EV/EBIT | ||||
---|---|---|---|---|---|
CN |
A
|
Apeloa Pharmaceutical Co Ltd
SZSE:000739
|
17.1B CNY | 16 | |
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -5 046 864.6 | |
US |
Eli Lilly and Co
NYSE:LLY
|
815.9B USD | 73.9 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
4.4T DKK | 40.3 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 17 702.3 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
351.9B USD | 14.7 | ||
US |
Merck & Co Inc
NYSE:MRK
|
329.7B USD | 58.1 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
195.3B GBP | 279.6 | ||
CH |
Roche Holding AG
SIX:ROG
|
191B CHF | 11.2 | ||
CH |
Novartis AG
SIX:NOVN
|
184.2B CHF | 13 | ||
US |
Pfizer Inc
NYSE:PFE
|
159.2B USD | 20.3 |
EV/EBIT Forward Multiples
Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.